ArticleOncotarget2017
Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 80 citations in OpenAlex.
- Article
- Peptide-MHC-targeted engineered virus-like particles enable selective priming and gene editing of tumor-specific T cells.Cell reports · 2026Article
- Therapeutic potential of tertiary lymphoid structures in breast cancer (Review).Molecular medicine reports · 2026Review
- Mechanisms of T cell-mediated antitumor immunity within tertiary lymphoid structures.Frontiers in immunology · 2026Review
- Generation of functional canine TIL products for solid tumors.Frontiers in immunology · 2026Article
- Advancing Cancer Immunotherapy: Chimeric Antigen Receptor (CAR)-T Cell Engineering through Novel Screening Methods.Biomolecules & therapeutics · 2026Review
- Peptide-MHC-targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells.Science advances · 2025Article
- LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapy.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Tumor infiltration therapy: from FDA approval to next-generation approaches.Clinical and experimental medicine · 2025Review
- Controlling T cell-tumor cell interaction with a biomimetic physical barrier for cancer immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy.Cell metabolism · 2025Article
- Optimal chemokine receptors for enhancing immune cell trafficking in adoptive cell therapy.Immunologic research · 2025Article
- Characteristics of successful expansion of tumor-infiltrating lymphocytes from colorectal cancer liver metastasis.Scientific reports · 2025Article
- Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.British journal of cancer · 2024Article
- Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy.Cancer immunology, immunotherapy : CII · 2024Article
- Review
- Integrating immunotherapy with conventional treatment regime for breast cancer patients- an amalgamation of armamentarium.Frontiers in immunology · 2024Review
- Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8Current pharmaceutical biotechnology · 2024Article
- Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes.Cancer reports (Hoboken, N.J.) · 2023Review
- Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.Cancer research communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive cell transfer (ACT) of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.